CLINICAL TRIALS PROFILE FOR PITAVASTATIN CALCIUM
✉ Email this page to a colleague
All Clinical Trials for pitavastatin calcium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Ajou University School of Medicine | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Asan Medical Center | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Chonbuk National University Hospital | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Chonnam National University Hospital | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Chungnam National University Hospital | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Dong-A University Hospital | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| NCT02056847 ↗ | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia | Completed | Eulji University Hospital | Phase 4 | 2013-09-01 | Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pitavastatin calcium
Condition Name
Clinical Trial Locations for pitavastatin calcium
Clinical Trial Progress for pitavastatin calcium
Clinical Trial Phase
Clinical Trial Sponsors for pitavastatin calcium
Sponsor Name
| Sponsor Name for pitavastatin calcium | |
| Sponsor | Trials |
| The Catholic University of Korea Uijeongbu St.Marys Hostpial | 1 |
| Hanllym University Medical Center | 1 |
| The Catholic University of Korea Yeouido St.Marys Hostpial | 1 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
